Thank you to all the shareholders who have registered their...

Thank you to all the shareholders who have registered their interest at [email protected]

For those wanting to protect their identity, you may wish to consider creating an email account with protonmail or another provider.

2022 is the year for Optiscan shareholders to become more informed, organised and active.

The company is now in the best position it has ever been in. There are many exciting developments happening this year and the company is in a strong financial position, meaning there are no financial impediments in the way.

Invivage's future use is more than just oral cancer screening and in surgery determining the margins of the cancer . Refer to my previous post containing a list of all the possible cancers that this device could be used on. Invivage's submission for FDA approval is close. After which the flood gates will open. The breast cancer surgical margin study is nearing completion. We must give credit to the board member who pushed that.

The FIVE2 the fluorescence in vivo endomicroscopy market is developing.

Zeiss CONVIVO is building up momentum, especially in Europe.

The only thing left is increasing the public's knowledge [awareness] of Optiscan's technology in respect to cancer detection and treatment. Public momentum will follow.

Finally, do not be surprised if in 2022 Optiscan is subject to takeover offers. Behind the scenes there is a lot of interest in this company and the technology.